{"organizations": [], "uuid": "efc92c70cb47783439d7b31b272085daf6d2b195", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180517.html", "section_title": "Archive News &amp; Video for Thursday, 17 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ultragenyx-kyowa-kirin-say-crysvit/brief-ultragenyx-kyowa-kirin-say-crysvita-met-main-goal-of-phase-3-study-idUSFWN1SO0P6", "country": "US", "domain_rank": 408, "title": "BRIEF-Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 Study", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.994, "site_type": "news", "published": "2018-05-17T20:39:00.000+03:00", "replies_count": 0, "uuid": "efc92c70cb47783439d7b31b272085daf6d2b195"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ultragenyx-kyowa-kirin-say-crysvit/brief-ultragenyx-kyowa-kirin-say-crysvita-met-main-goal-of-phase-3-study-idUSFWN1SO0P6", "ord_in_thread": 0, "title": "BRIEF-Ultragenyx, Kyowa Kirin Say Crysvita Met Main Goal Of Phase 3 Study", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ultragenyx pharmaceutical inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "kyowa kirin", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 17 (Reuters) - Ultragenyx Pharmaceutical Inc:\n* ULTRAGENYX AND KYOWA KIRIN ANNOUNCE TOPLINE PHASE 3 STUDY RESULTS DEMONSTRATING SUPERIORITY OF CRYSVITA® (BUROSUMAB) TREATMENT TO ORAL PHOSPHATE AND ACTIVE VITAMIN D IN CHILDREN WITH X-LINKED HYPOPHOSPHATEMIA (XLH)\n* ULTRAGENYX PHARMACEUTICAL INC - PHASE 3 STUDY OF CRYSVITA® (BUROSUMAB) MET ITS PRIMARY ENDPOINT\n* ULTRAGENYX PHARMACEUTICAL - PHASE 3 STUDY OF CRYSVITA SHOWED IMPROVEMENT IN IMPORTANT METABOLIC AND FUNCTIONAL MEASURES WITH CRYSVITA TREATMENT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-17T20:39:00.000+03:00", "crawled": "2018-05-18T19:46:23.000+03:00", "highlightTitle": ""}